Similarly, the phase III FLAURA trial unequivocally showed that Osimertinib outperforms first-generation EGFR-TKIs such as Gefitinib and Erlotinib as a first-line treatment for EGFR-mutation-positive advanced NSCLC, with significant benefits in both PFS (hazard ratio [HR] for disease progression or death, 0.46; p < 0.001) and OS (HR for mortality, 0.80; p = 0.046) [6,17]. Here, EGFR is linked to non-small cell lung carcinoma.